Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a positive outlook: Kiniksa Pharmaceuticals has a consensus “Moderate Buy” rating, with eight buy ratings and two holds. The average 12-month price target is $87.38, while several firms recently raised targets to between $99 and $107.
• Recent financial results exceeded revenue expectations: The company reported quarterly EPS of $0.30, in line with estimates, while revenue of $243.6 million surpassed the $226.5 million consensus forecast.
• Shares have surged and institutional ownership is significant: KNSA opened at $78.08, near its 52-week high of $82.94, after trading as low as $33.25. Institutional investors own 53.95% of the stock, while an insider recently sold shares worth approximately $299,000.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $87.3750.

KNSA has been the topic of several recent analyst reports. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 30th. JPMorgan Chase & Co. upped their price target on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 12th. Finally, Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, Director G Bradley Cole sold 3,673 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company's stock, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 51.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KNSA. Corient Private Wealth LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 26.8% during the 2nd quarter. Corient Private Wealth LP now owns 10,214 shares of the company's stock valued at $653,000 after buying an additional 2,158 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth $256,000. California State Teachers Retirement System increased its stake in shares of Kiniksa Pharmaceuticals International by 6,384.0% in the second quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company's stock worth $174,049,000 after acquiring an additional 2,679,673 shares during the last quarter. TD Waterhouse Canada Inc. raised its holdings in shares of Kiniksa Pharmaceuticals International by 4.5% during the second quarter. TD Waterhouse Canada Inc. now owns 16,691 shares of the company's stock worth $1,049,000 after acquiring an additional 724 shares in the last quarter. Finally, Nykredit A S purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $34,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $78.08 on Monday. Kiniksa Pharmaceuticals International has a fifty-two week low of $33.25 and a fifty-two week high of $82.94. The firm's 50 day simple moving average is $69.89 and its 200-day simple moving average is $56.24. The company has a market cap of $6.09 billion, a P/E ratio of 80.49 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. On average, analysts expect that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source